TCRX

TScan Therapeutics, Inc. (TCRX) - 10-K Summary

Business Context and Reporting Period

Company: TScan Therapeutics, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: TScan is a clinical-stage biotechnology company developing T cell receptor (TCR)-engineered T cell (TCR-T) therapies for cancer and autoimmune disorders. The company's lead product candidate, TSC-101, targets acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in patients undergoing allogeneic hematopoietic cell transplantation (HCT). In Q4 2025, the company reached an agreement with the FDA on a registrational path for TSC-101. Concurrently, the company paused enrollment in its solid tumor Phase 1 trial (PLEXI-T) to prioritize its hematologic program and focus preclinical efforts on in vivo engineering for solid tumors.

Key Financial Metrics

Note: Revenue is derived primarily from the collaboration agreement with Amgen. The company has no product sales revenue.

Material Changes vs. Prior Period

• Revenue Increase: Revenue increased by $7.5 million (267%) to $10.3 million, driven by the timing of research activities under the Amgen collaboration agreement.
• Expense Growth: Total operating expenses increased by $8.5 million to $146.1 million. R&D expenses rose $6.8 million due to increased laboratory supplies and facility costs, while G&A expenses rose $1.7 million.
• Strategic Restructuring: In November 2025, the company implemented a workforce reduction of approximately 30% (66 roles) to prioritize the heme program. This resulted in $2.0 million in restructuring charges ($1.6M in R&D, $0.4M in G&A).
• Debt Refinancing: The company repaid its K2HV loan in December 2024 and entered a new $52.5 million term loan facility with Silicon Valley Bank (SVB), of which $32.5 million was funded. This replaced the previous debt structure.
• Cash Flow: Net cash used in operating activities increased to $135.3 million in 2025 from $110.8 million in 2024. Net cash provided by investing activities turned positive ($109.4 million) due to maturities of marketable securities exceeding purchases.

Guidance, Outlook, and Risks

Outlook and Guidance:

• Liquidity: Management believes existing cash and cash equivalents ($152.4 million) will fund operations into the second half of 2027.
• Cost Savings: The November 2025 restructuring is expected to produce annual cost savings of $45.0 million in 2026 and 2027.
• Clinical Milestones: The company intends to initiate a registrational trial for TSC-101 in the second quarter of 2026. Phase 1 studies for TSC-102 candidates are planned for the second half of 2026.

Key Risks and Contingencies:

• Capital Requirements: The company expects to incur significant losses for the foreseeable future and will require substantial additional capital to complete development and commercialization.
• Development Risk: Success depends on the proprietary platform; failure of one product candidate could impact others due to shared manufacturing and technology.
• Regulatory Uncertainty: The regulatory approval process is lengthy, and the novel nature of TCR-T therapies creates challenges.
• Debt Covenants: The SVB loan agreement includes restrictive covenants limiting asset disposal, additional indebtedness, and equity repurchases.

Investor Verification Checklist

• Cash Runway: Verify the accuracy of the "second half of 2027" liquidity estimate against current burn rates and potential delays in clinical trials.
• Amgen Revenue Recognition: Review the specific terms of the Amgen collaboration to understand the timing and probability of future milestone payments (over $500 million potential).
• Restructuring Impact: Monitor whether the anticipated $45 million in annual cost savings materializes in 2026 financials.
• Debt Terms: Review the SVB Loan Agreement covenants and the conditions required to access the second tranche of $20.0 million.
• Clinical Data: Await data readouts from the TSC-101 ALLOHA trial to validate the registrational path agreed upon with the FDA.